On January 5, 2026, Novo Nordisk announced it had launched an oral tablet version of its injectable GLP-1 weight-loss medication, Wegovy (semaglutide).


On January 5, 2026, Novo Nordisk announced it had launched an oral tablet version of its injectable GLP-1 weight-loss medication, Wegovy (semaglutide).
